1.
Int Med Case Rep J
; 15: 735-738, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36545548
RESUMO
Two critically ill COVID-19 infected patients, who had exhausted all available treatment options, were treated with the small-molecule RRx-001 with subsequent improvement. RRx-001, a first-in-class small molecule with anti-inflammatory, vascular normalizing and macrophage-repolarizing properties, has been safely administered 300+ patients in clinical trials. This is the first report of RRx-001 treatment of COVID-19.